Embodiments disclosed include systems, devices, and methods for analysis of samples containing particles used for gene delivery to determine a quality of the sample and/or an indication that the gene delivery particles are in a full, partial, and/or empty state. The present disclosure also relates to determining a protein and/or NA content in samples with known proportions of gene delivery particles in a full, partial, and/or empty state and based on the determination, establish a relationship between NA content and proportions of gene delivery particles in a full state. The present disclosure also relates to using such an established relationship to predict a proportion of the gene delivery particles in a full, partial, and/or empty state in test samples having the gene delivery particles in an unknown state.

An apparatus and method for generating a treatment plan for salutogenesis, the apparatus comprising a at least a processor and a memory communicatively connected to the processor, the memory containing instructions configuring the at least a processor to receive physiological data associated with a user and comprising a plurality of biomarkers, wherein the plurality of biomarkers comprise at least a glycocalyx degradation biomarker, determine a concentration for each at least a glycocalyx degradation biomarker of the plurality of biomarkers, classify the at least a glycocalyx degradation biomarker to a disease condition and a treatment label as a function of the concentration, and generate a treatment plan as a function of the disease condition and the treatment label.

An apparatus and method for generating a treatment plan for salutogenesis, the apparatus comprising a at least a processor and a memory communicatively connected to the processor, the memory containing instructions configuring the at least a processor to receive physiological data associated with a user and comprising a plurality of biomarkers, wherein the plurality of biomarkers comprise at least a glycocalyx degradation biomarker, determine a concentration for each at least a glycocalyx degradation biomarker of the plurality of biomarkers, classify the at least a glycocalyx degradation biomarker to a disease condition and a treatment label as a function of the concentration, and generate a treatment plan as a function of the disease condition and the treatment label.

A system for generating a novel molecular structure using a protein structure is disclosed. One or more processors generate a protein voxel representation of a protein structure that includes a multichannel three-dimensional (3D) grid that includes a plurality of channels. A cavity region is detected in the protein voxel representation based on a combination of rule-based detection and a deep learning based model. A cavity voxel representation of the cavity region is generated based on upscaling of a regional voxel of the detected cavity region. A ligand voxel representation of a ligand structure is generated based on the cavity voxel representation. A 3D voxel descriptor is determined for a protein-ligand complex based on the protein voxel representation and the ligand voxel representation. A simplified molecular-input line-entry system (SMILES) of a novel molecular structure is generated using a rich 3D embedding vector, which is based on the 3D voxel descriptor.

A system for generating a novel molecular structure using a protein structure is disclosed. One or more processors generate a protein voxel representation of a protein structure that includes a multichannel three-dimensional (3D) grid that includes a plurality of channels. A cavity region is detected in the protein voxel representation based on a combination of rule-based detection and a deep learning based model. A cavity voxel representation of the cavity region is generated based on upscaling of a regional voxel of the detected cavity region. A ligand voxel representation of a ligand structure is generated based on the cavity voxel representation. A 3D voxel descriptor is determined for a protein-ligand complex based on the protein voxel representation and the ligand voxel representation. A simplified molecular-input line-entry system (SMILES) of a novel molecular structure is generated using a rich 3D embedding vector, which is based on the 3D voxel descriptor.

Displaying an indication of ancestral data is disclosed. An indication that a genetic interval corresponds to a reference interval that has a likelihood of having one or more ancestral origins is received. One or more graphic display parameters are determined based at least in part on the indication. An indication of the one or more ancestral origins is visually displayed using the one or more graphic display parameters.

The present invention comprises the capture and display of arthropod, human and arthropod-based metadata, which is capable of tracking and displaying the metadata, which is time and location-based, in order to show migration paths of arthropods and/or the diseases they have the potential to carry. This real-time view can help predict future arthropod and disease based on various scenarios such as, but not limited to: increased exposure based on the following: a user's geo-location, date and/or time of year, carrier type, etc. These variables can then assist with the education, awareness and potential prevention of disease.

The present invention comprises the capture and display of arthropod, human and arthropod-based metadata, which is capable of tracking and displaying the metadata, which is time and location-based, in order to show migration paths of arthropods and/or the diseases they have the potential to carry. This real-time view can help predict future arthropod and disease based on various scenarios such as, but not limited to: increased exposure based on the following: a user's geo-location, date and/or time of year, carrier type, etc. These variables can then assist with the education, awareness and potential prevention of disease.

The present invention relates to a biomarker for diagnosis of overactive bladder (OAB) disease, and a method for screening a drug using the biomarker. The markers described in the present invention can effectively detect or diagnose the onset of OAB by distinguishing them from normal populations. In particular, OAB-specific protein markers released into urine enable simple and rapid OAB diagnosis in a non-invasive manner. In addition, by selecting an agent that changes, particularly normalizes the expression and activity of the markers selected in the present invention, more effective preventative or therapeutic agents of OAB disease can be screened.

The present invention relates to a biomarker for diagnosis of overactive bladder (OAB) disease, and a method for screening a drug using the biomarker. The markers described in the present invention can effectively detect or diagnose the onset of OAB by distinguishing them from normal populations. In particular, OAB-specific protein markers released into urine enable simple and rapid OAB diagnosis in a non-invasive manner. In addition, by selecting an agent that changes, particularly normalizes the expression and activity of the markers selected in the present invention, more effective preventative or therapeutic agents of OAB disease can be screened.